Previous to the publication of the EC proposal to review the EU pharmaceutical legislation, EPHA had called for more transparency of the research and development (R&D) costs for pharmaceutical products. Without clear knowledge of pharmaceutical R&D costs, it...
By Charlotte Roffiaen, France Assos Santé With the COVID-19 pandemic and the multiplication of antibiotic supply disruptions, the fight against medicine shortages has become one of the first priorities of the EU and its Member States. This is perfectly reflected in...
By Dr Ward Rommel, Chair, Access to Medicines Task Force of Association of European Cancer Leagues (ECL) – @CancerLeagues & @WardRommel | #LetsTalkAccess In Europe, around 2.7 million people are diagnosed with cancer every year – and this number is set to...
Guest article by Feras Kesabji [1] and János Sándor [1,2] [1] Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen [2] ELKH-DE Public Health Research Group, Department of Public Health and Epidemiology, Faculty of Medicine,...
Guest article by Jan Penfrat, Senior Policy Advisor, European Digital Rights (EDRi) The European Health Data Space (EHDS) is a new EU law proposed to improve how people’s medical data can be used. That includes the ability for hospitals and physicians to share...
Guest article by Diogo Teixeira Pereira, Policy Assistant, European Association of Hospital Pharmacists (EAHP) Access to modern digital health infrastructure is essential for improving the way health care is delivered to patients across the EU. Hospital pharmacists as...
